BMJ finds 96% of oncology drug developers inadequately include minority groups

The FDA approved 59 novel oncology therapeutics, sponsored by 25 different pharmaceutical companies, between 2012 and 2017. A study by Varma and colleagues reported in the British Medical Journal (BMJ) this month found that only one of these companies included a sufficient number of minority groups in their clinical trials. Just 56% of the sponsors adequately represented women in all clinical trials, and only 24% had a sufficient representation of older adults.